Centessa Pharmaceuticals plc (CNTA)

$13.72

up-down-arrow $-0.03 (-0.22%)

As on 29-Apr-2025 16:00EDT

Centessa Pharmaceuticals plc (CNTA) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 13.47 High: 14.00

52 Week Range

Low: 7.75 High: 19.09

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $1,831 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    4.56

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    0.02

  • ROEROE information

    -0.74 %

  • ROCEROCE information

    -64.53 %

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    3.52

  • EPSEPS information

    -2.07

5 Years Aggregate

CFO

$-514.11 Mln

EBITDA

$-533.58 Mln

Net Profit

$-766.06 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Centessa Pharmaceuticals (CNTA)
-18.09 -5.96 -17.30 53.81 15.74 -- --
BSE Sensex
2.61 3.71 5.78 8.89 11.76 20.11 11.35
As on 29-Apr-2025
2024
2023
2022
2018
Centessa Pharmaceuticals (CNTA)
109.15 156.77 -72.47 0.00
BSE Sensex
8.10 18.74 4.44 5.87
BSE Sensex
8.10 18.74 4.44 5.87

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peer

View All
Company
Price ($) Market Cap ($ Mln) P/E Ratio ROE
38.55 10,593.45 21.84 23.13
306.35 8,570.17 22.78 66.44
27.82 10,589.59 -- -28.77
107.24 10,559.67 32.44 14.16

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of...  idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT  Read more

  • CEO & Director

    Dr. Saurabh Saha M.D., Ph.D.

  • CEO & Director

    Dr. Saurabh Saha M.D., Ph.D.

  • Headquarters

    Altrincham

  • Website

    https://centessa.com

Edit peer-selector-edit
loading...
loading...

FAQs for Centessa Pharmaceuticals plc (CNTA)

The total asset value of Centessa Pharmaceuticals plc (CNTA) stood at $ 577 Mln as on 31-Dec-24

The share price of Centessa Pharmaceuticals plc (CNTA) is $13.72 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 15.74% in the last 3 years.

Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 1,831 Mln as on 29-Apr-2025. As per Value Research classification, it is a company.

Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Centessa Pharmaceuticals plc (CNTA) and enter the required number of quantities and click on buy to purchase the shares of Centessa Pharmaceuticals plc (CNTA).

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

The CEO & director of Dr. Saurabh Saha M.D., Ph.D.. is Centessa Pharmaceuticals plc (CNTA), and CFO & Sr. VP is Dr. Saurabh Saha M.D., Ph.D..

There is no promoter pledging in Centessa Pharmaceuticals plc (CNTA).

Centessa Pharmaceuticals plc (CNTA) Ratios
Return on equity(%)
-73.93
Operating margin(%)
--
Net Margin(%)
--
Dividend yield(%)
--

No, TTM profit after tax of Centessa Pharmaceuticals plc (CNTA) was $0 Mln.